<DOC>
	<DOCNO>NCT01032486</DOCNO>
	<brief_summary>The main objective study evaluate effect Azilect® sleep disturbance Parkinson 's Disease patient , 2 month treatment .</brief_summary>
	<brief_title>Study Rasagiline Effect Sleep Trial ( REST ) Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>idiopathic Parkinson 's disease . eligible Azilect® treatment per Canadian product monograph exclusion ( e.g . drugdrug interaction , contraindication , warning precaution ) base Canadian product monograph . investigational drug within 30 day prior study use Azilect® selegiline within 60 day prior study significant medical condition</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Rasagiline</keyword>
	<keyword>Sleep</keyword>
	<keyword>Sleepiness</keyword>
	<keyword>Parkinson 's Disease Sleep Scale</keyword>
	<keyword>Epworth Sleepiness Scale</keyword>
</DOC>